You have full text access to this OnlineOpen article

Cancer

Cover image for Cancer

1 August 2006

Volume 107, Issue 3

Pages 439–660

  1. Review Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Errata
    1. You have full text access to this OnlineOpen article
      Current status of lymph node-positive prostate cancer : Incidence and predictors of outcome (pages 439–450)

      Gregory P. Swanson, Ian M. Thompson and Joseph Basler

      Article first published online: 22 JUN 2006 | DOI: 10.1002/cncr.22034

      Although the incidence of positive lymph nodes in patients with prostate cancer has declined, there still are significant numbers of patients who have lymph node-positive disease, and it remains a therapeutic dilemma.

    2. You have full text access to this OnlineOpen article
      Long-term effects of the treatment of polycythemia vera with recombinant interferon-α (pages 451–458)

      Richard T. Silver

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22026

      Long-term interferon is effective in the treatment of polycythemia vera. It induces remission in a large percent of patients.

    3. You have full text access to this OnlineOpen article
      Emerging implications of nanotechnology on cancer diagnostics and therapeutics (pages 459–466)

      Alex G. Cuenca, Huabei Jiang, Steven N. Hochwald, Matthew Delano, William G. Cance and Stephen R. Grobmyer

      Article first published online: 22 JUN 2006 | DOI: 10.1002/cncr.22035

      The integration of nanotechnology into cancer diagnostics and therapeutics is rapidly advancing field. There is a need for wide understanding of these emerging concepts. The development of new nanoscale platforms offers great potential for improvements in the care of cancer patients in the near future.

  2. Original Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Errata
    1. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes (pages 467–471)

      Maartje C. van Rijk, Johannes L. Peterse, Omgo E. Nieweg, Hester S. A. Oldenburg, Emiel J. Th. Rutgers and Bin B. R. Kroon

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22069

      In patients with breast cancer, micrometastases and submicrometastases are increasingly found in sentinel nodes when step sectioning and/or immunohistochemical staining are applied. Additional treatment of the axilla should be offered in patients with micrometastases, but ALND can be ommitted in patients with submicrometastases in the sentinel node.

    2. You have full text access to this OnlineOpen article
      Impact of chemotherapy regimens prior to endocrine therapy : Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial (pages 472–480)

      Aman U. Buzdar, Jean-Paul Guastalla, Jean-Marc Nabholtz, Jack Cuzick and on behalf of the ATAC Trialists' Group

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22042

      In this retrospective, exploratory analysis of 68-month data from the ATAC trial, the authors investigated the impact of prior chemotherapy, including an assessment of different chemotherapy regimens, on time to recurrence. The benefit of anastrozole was observed whether or not the patient had received prior chemotherapy, and was independent of the type of chemotherapy given.

    3. Gastrointestinal Tract
      You have full text access to this OnlineOpen article
      Oncogenic T-antigen of JC virus is present frequently in human gastric cancers (pages 481–488)

      Sung Kwan Shin, Mei-Shu Li, Florentine Fuerst, Erin Hotchkiss, Richard Meyer, Tae Kim II, Ajay Goel and C. Richard Boland

      Article first published online: 22 JUN 2006 | DOI: 10.1002/cncr.22028

      JC virus (JCV) has been considered an innocent and passive passenger in humans; however, it can cause progressive, multifocal leukoencephalopathy in patients who have compromised immune status. The current study was designed to investigate whether JCV sequences and expression were found in human gastric cancers, possibly suggesting a role for JCV in the process of gastric carcinogenesis.

    4. Genitourinary Disease
      You have full text access to this OnlineOpen article
      The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer : A Multivariate Analysis of Southwest Oncology Group Study 8894 (pages 489–496)

      Tomasz M. Beer, Catherine M. Tangen, Lisa B. Bland, Maha Hussain, Bryan H. Goldman, Thomas G. DeLoughery and E. David Crawford

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22029

      In patients with previously untreated metastatic prostate cancer, hemoglobin decline after 3 months of androgen deprivation therapy was associated with shorter survival and progression-free survival after adjustment for disease status and other baseline covariates. While race alone was not a strong predictor of death or disease progression, the effect of baseline hemoglobin an overall and progression-free survival varied significantly by race.

    5. You have full text access to this OnlineOpen article
      Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma (pages 497–505)

      Nizar Tannir, Eric Jonasch, Lance C. Pagliaro, Paul Mathew, Arlene Siefker-Radtke, Laurence Rhines, Patrick Lin, Rita Tibbs, Kim-Anh Do, Sue-Hwa Lin and Shi-Ming Tu

      Article first published online: 22 JUN 2006 | DOI: 10.1002/cncr.22038

      A bone-targeted regimen combining zoledronate, thalidomide, and interferon-γ was well tolerated and might provide clinical benefit for selected patients with renal cell carcinoma and bone metastases.

    6. You have full text access to this OnlineOpen article
      Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder (pages 506–513)

      Atreya Dash, Matthew D. Galsky, Andrew J. Vickers, Angel M. Serio, Theresa M. Koppie, Guido Dalbagni and Bernard H. Bochner

      Article first published online: 13 JUN 2006 | DOI: 10.1002/cncr.22031

      Cisplatin-based combination perioperative chemotherapy has been shown to improve survival in patients with high-risk localized urothelial carcinoma of the bladder. However, the widespread use of such treatment may be limited by the high frequency of baseline renal impairment in this patient population. Using a cutoff creatinine clearance of <60 mL/min (calculated by Cockroft-Gault) to determine eligibility for perioperative chemotherapy, 28% (95% confidence interval, 24%–31%) of patients were ineligible. The exact proportion ineligible differed substantially with different formulas used to calculate creatinine clearance, but elderly patients were particularly likely to be ineligible.

    7. You have full text access to this OnlineOpen article
      Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer (pages 514–520)

      Neesha A. Rodrigues, Ming-Hui Chen, William J. Catalona, Kimberly A. Roehl, Jerome P. Richie and Anthony V. D'Amico

      Article first published online: 22 JUN 2006 | DOI: 10.1002/cncr.22018

      Prostate-specific antigen (PSA) nadir >0.2 ng/mL after androgen-deprivation therapy and Gleason scores ≥8 were associated significantly with a short time to prostate cancer-specific mortality after biochemical recurrence in men who had initial PSA doubling times ≤6 months. Men with these factors would be ideal candidates for Phase III studies evaluating the impact of new systemic treatments on survival.

    8. You have full text access to this OnlineOpen article
      Obesity and survival after radical prostatectomy: A 10-year prospective cohort study (pages 521–529)

      Sameer A. Siddiqui, Brant A. Inman, Shomik Sengupta, Jeffrey M. Slezak, Eric J. Bergstralh, Bradley C. Leibovich, Horst Zincke and Michael L. Blute

      Article first published online: 13 JUN 2006 | DOI: 10.1002/cncr.22030

      Obese patients appear to have worse pathologic features at the time of prostatectomy. Despite these features, long-term oncologic outcomes, including cancer-specific survival, remain the same regardless of BMI.

    9. You have full text access to this OnlineOpen article
      Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer (pages 530–535)

      M. Dror Michaelson, Donald S. Kaufman, Philip Kantoff, William K. Oh and Matthew R. Smith

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22043

      There is no evidence for additive or synergistic effects of combination therapy with atrasentan and zoledronic acid on bone turnover markers in men with metastatic prostate cancer.

    10. Gynecologic Oncology
      You have full text access to this OnlineOpen article
      Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer : A cost-effectiveness analysis (pages 536–543)

      Rodney P. Rocconi, Ashley S. Case, J. Michael Straughn Jr., Jacob M. Estes and Edward E. Partridge

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22045

      A conservative decision analysis model calculated that best supportive care was the only cost-effective strategy for the treatment of platinum-resistant epithelial ovarian cancer. However, based on sensitivity analyses, second-line monotherapy appears to be a reasonable cost-effective strategy in this patient population.

    11. Head and Neck Disease
      You have full text access to this OnlineOpen article
      Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly : A prospective randomized study in squamous cell head and neck cancer (pages 544–553)

      Anke Petra Jellema, Ben J. Slotman, Martin J. Muller, C. Rene Leemans, Ludi E. Smeele, Klaas Hoekman, Neil K. Aaronson and Johannes A. Langendijk

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22020

      In a randomized trial, the nondaily administration of amifostine was investigated in patients with head and neck cancer who received radiotherapy. The late radioprotective properties of a 3-times-per-week dose of amifostine appeared to be similar to that of a 5-times-per-week schedule, but toxicity may hamper implementation in clinical practice.

    12. You have full text access to this OnlineOpen article
      Primary versus radiation-associated craniofacial osteosarcoma : Biologic and clinicopathologic comparisons (pages 554–562)

      Jonathan B. McHugh, Dafydd G. Thomas, Joseph M. Herman, Michael E. Ray, Laurence H. Baker, N. Volkan Adsay, Raja Rabah and David R. Lucas

      Article first published online: 22 JUN 2006 | DOI: 10.1002/cncr.22019

      The current study compares primary with radiation-associated osteosarcoma of the craniofacial bones. In addition to being more aggressive with poorer outcomes, the radiation-associated tumors had higher rates of adverse prognostic markers such as high histologic grade, p53, Ki-67, and ezrin expression, and TP53 mutations.

    13. You have full text access to this OnlineOpen article
      Overexpression of podoplanin in oral cancer and its association with poor clinical outcome (pages 563–569)

      Ping Yuan, Stephane Temam, Adel El-Naggar, Xian Zhou, Diane D. Liu, J. Jack Lee and Li Mao

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22061

      Podoplanin is involved in oral tumorigenesis and may serve as a predictor for lymph node metastasis and poor clinical outcome.

    14. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      T-cell large granular lymphocyte leukemia : A report on the treatment of 29 patients and a review of the literature (pages 570–578)

      Nnenna Osuji, Estella Matutes, Geir Tjonnfjord, Henri Grech, Ilaria Del Giudice, Andrew Wotherspoon, John G. Swansbury and Daniel Catovsky

      Article first published online: 22 JUN 2006 | DOI: 10.1002/cncr.22032

      The authors investigated the treatment and long-term follow-up of 29 patients with T-cell large granular lymphocyte leukemia, and their results confirmed the efficacy of cyclosporin A and methotrexate given continuously and recognized the potential utility of the purine analogues and alemtuzumab for the treatment of this disease. Second malignancies and persistent bone marrow disease were noteworthy findings, and an optimal treatment approach remains to be defined.

    15. Hepatobiliary Disease
      You have full text access to this OnlineOpen article
      Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma (pages 579–590)

      Yu-Lueng Shih, Rong-Yuan Shyu, Chung-Bao Hsieh, Hung-Cheng Lai, Kuo-Yu Liu, Tang-Yuan Chu and Ya-Wen Lin

      Article first published online: 22 JUN 2006 | DOI: 10.1002/cncr.22023

      The authors investigated whether methylation of the secreted frizzled-related protein 1 gene (SFRP1) promoter was common in hepatocellular carcinoma (HCC) and whether it may influence SFRP1 expression. The results indicated that promoter hypermethylation of SFRP1 is a common event in HCC and plays an important role in the regulation of SFRP1 expression.

    16. You have full text access to this OnlineOpen article
      Proton beam therapy for hepatocellular carcinoma with limited treatment options (pages 591–598)

      Masaharu Hata, Koichi Tokuuye, Shinji Sugahara, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Kayoko Ohnishi, Keiko Nemoto, Kiyoshi Ohara, Yasushi Matsuzaki and Yasuyuki Akine

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22039

      Proton beam therapy was given safely and effectively to a wide spectrum of patients with hepatocellular carcinoma. The results suggested that this method was tolerable and effective even for patients who had severe coexisting diseases or unfavorable conditions for whom other treatment modalities were contraindicative or unfeasible.

    17. Lung Disease
      You have full text access to this OnlineOpen article
      Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer : West Japan Thoracic Oncology Group (WJTOG) 0104 (pages 599–605)

      Nobuyuki Yamamoto, Kazuhiko Nakagawa, Hisao Uejima, Takahiko Sugiura, Yoshiki Takada, Shun-ichi Negoro, Kaoru Matsui, Tatsuhiko Kashii, Minoru Takada, Yoichi Nakanishi, Terufumi Kato and Masahiro Fukuoka

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22024

      In this randomized Phase II study, the efficacy and toxicity of combined gemcitabine and carboplatin (GC) and of combined gemcitabine and vinorelbine (GV) were compared as treatment for patients with advanced nonsmall cell lung cancer (NSCLC). Although the GV and GC regimens had different toxicity profiles, there was no significant difference in survival among patients with NSCLC.

    18. Sarcoma
      You have full text access to this OnlineOpen article
      Epithelioid sarcoma: Still an only surgically curable disease (pages 606–612)

      Sebastiaan A. H. J. de Visscher, Robbert J. van Ginkel, Theo Wobbes, René P. H. Veth, Suzanne E. ten Heuvel, Albert J. H. Suurmeijer and Harad J. Hoekstra

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22037

      Epithelioid sarcoma is a rare soft tissue tumor with a high locoregional and distal failure rate. For patients with these tumors, optimal imaging with computed tomography scanning, ultrasonography, and lymph node biopsy may improve staging and alter disease outcomes.

    19. Discipline

      Pediatric Oncology
      You have full text access to this OnlineOpen article
      Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis : Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study (pages 613–619)

      Akira Morimoto, Satoshi Ikushima, Naoko Kinugawa, Eiichi Ishii, Urara Kohdera, Masahiro Sako, Junichiro Fujimoto, Fumio Bessho, Keizo Horibe, Yukiko Tsunematsu, Shinsaku Imashuku and for the Japan Langerhans Cell Histiocytosis Study Group

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.21985

      Treatment outcomes of multifocal childhood Langerhans cell histiocytosis (LCH) have been not satisfactory, with poor therapeutic responses, high mortality, and a high incidence of reactivation with late sequelae; and the Japan LCH Study Group-96 (JLSG-96) protocol was conducted prospectively from 1996 to 2001 to address these issues. On a protocol of induction therapy with combined cytosine arabinoside, vincristine, and prednisolone followed by 6 months of maintenance therapy, pediatric patients with multifocal LCH attained very low mortality.

    20. Psychological Oncology
      You have full text access to this OnlineOpen article
      Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote (pages 620–630)

      Thomas D. Denberg, Trisha V. Melhado and John F. Steiner

      Article first published online: 26 JUN 2006 | DOI: 10.1002/cncr.22033

      Patient treatment preferences in localized prostate carcinoma are not based on careful assessments of numerical risks for various clinical outcomes. Instead, feelings of fear and uncertainty contribute to a desire for rapid treatment, and specific preferences are profoundly influenced by misconceptions, especially about prostatectomy, and by anecdotes about the experiences of others with cancer.

    21. Radiation Oncology
      You have full text access to this OnlineOpen article
      Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer (pages 631–639)

      Sara S. Strom, Ashish M. Kamat, Stephen K. Gruschkus, Yun Gu, Sijin Wen, Min Rex Cheung, Louis L. Pisters, Andrew K. Lee, Charles J. Rosser and Deborah A. Kuban

      Article first published online: 26 JUN 2006 | DOI: 10.1002/cncr.22025

      In the current study it was found that obesity was an independent predictor of biochemical and clinical failure among 873 prostate cancer patients treated with radiotherapy. The findings validate the important role of obesity in prostate cancer progression and suggest a link to the biologic basis of tumor progression that can be therapeutically exploited.

    22. Translational Research
      You have full text access to this OnlineOpen article
      Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors (pages 640–648)

      Francesca Re, Carlo Staudacher, Loris Zamai, Viviana Vecchio and Marco Bregni

      Article first published online: 27 JUN 2006 | DOI: 10.1002/cncr.22002

      Preliminary data are reported demonstrating that primary tumor cells are susceptible to killer cell immunoglobulin (Ig)-like receptors-incompatible natural killer cell-mediated killing.

    23. You have full text access to this OnlineOpen article
      Thapsigargin resistance in human prostate cancer cells (pages 649–659)

      John P. O'Neill, Chidambaram Natesa Velalar, Dong Ik Lee, Bin Zhang, Takeo Nakanishi, Yao Tang, Florin Selaru, Douglas Ross, Stephen J. Meltzer and Arif Hussain

      Article first published online: 12 JUN 2006 | DOI: 10.1002/cncr.22027

      Thapsigargin (TG) is a potent inhibitor of sarcoplasmic/endoplasmic reticulum Ca2+ ATPases. TG-based prodrugs are being developed for the treatment of prostate cancer. To develop optimal TG-based therapeutics it is important to understand the mechanisms of resistance to TG that may potentially occur in cancer cells.

  3. Errata

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Errata
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION